S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
CVE:LBL

Lattice Biologics Stock Forecast, Price & News

C$0.04
0.00 (0.00 %)
(As of 06/3/2021)
Add
Compare
Today's Range
C$0.04
C$0.04
50-Day Range
C$0.04
C$0.04
52-Week Range
C$0.03
C$0.13
Volume114,000 shs
Average Volume468,022 shs
Market CapitalizationC$5.13 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LBL News and Ratings via Email

Sign-up to receive the latest news and ratings for Lattice Biologics and its competitors with MarketBeat's FREE daily newsletter.


About Lattice Biologics

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Headlines

IIROC Trading Halt - LBL
June 9, 2021 |  ca.finance.yahoo.com
Lattice Announces Strategic Advisory Board
March 31, 2021 |  finance.yahoo.com
Lattice Biologics Ltd. Announces Resignation of Director
March 3, 2021 |  uk.finance.yahoo.com
News for Lattice Biologics Ltd
December 2, 2020 |  markets.businessinsider.com
Lattice Biologics Ltd. Reports Q3 2020 Results
August 31, 2020 |  businesswire.com
Lattice Biologics Ltd. (LBLTF)
August 14, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
C$1.56 million
Book Value
C$0.00 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$5.13 million
Next Earnings Date
1/27/2022 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Lattice Biologics (CVE:LBL) Frequently Asked Questions

What stocks does MarketBeat like better than Lattice Biologics?

Wall Street analysts have given Lattice Biologics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lattice Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Lattice Biologics' next earnings date?

Lattice Biologics is scheduled to release its next quarterly earnings announcement on Thursday, January 27th 2022.
View our earnings forecast for Lattice Biologics
.

How has Lattice Biologics' stock price been impacted by Coronavirus (COVID-19)?

Lattice Biologics' stock was trading at C$0.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LBL shares have increased by 33.3% and is now trading at C$0.04.
View which stocks have been most impacted by COVID-19
.

Who are Lattice Biologics' key executives?

Lattice Biologics' management team includes the following people:
  • Mr. Guy S. Cook, Chairman, Pres & CEO (Age 56, Pay $360k)
  • Ms. Donna Medina, Interim Chief Financial Officer

What other stocks do shareholders of Lattice Biologics own?

What is Lattice Biologics' stock symbol?

Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL."

How do I buy shares of Lattice Biologics?

Shares of LBL and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Lattice Biologics' stock price today?

One share of LBL stock can currently be purchased for approximately C$0.04.

How much money does Lattice Biologics make?

Lattice Biologics has a market capitalization of C$5.13 million and generates C$1.56 million in revenue each year.

What is Lattice Biologics' official website?

The official website for Lattice Biologics is www.latticebiologics.com.

Where are Lattice Biologics' headquarters?

How can I contact Lattice Biologics?

Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The company can be reached via phone at +1-604-2356701.


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.